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Abstract
This study evaluated the potential of poly(iso-butyl cyanoacrylate) (PBCA) nanocapsules
dispersed in a biocompatible microemulsion to facilitate the absorption of insulin following
intragastric administration to diabetic rats. Insulin-loaded PBCA nanocapsules were prepared
in-situ in a biocompatible water-in-oil microemulsion by interfacial polymerisation. The
microemulsion consisted of a mixture of medium-chain mono-, di- and tri-glycerides as the oil
component, polysorbate 80 and sorbitan mono-oleate as surfactants and an aqueous solution
of insulin. Resulting nanocapsules were approximately 200 nm in diameter and demonstrated
a high ef ciency of insulin entrapment ( " 80%). In-vitro release studies showed that PBCA
nanocapsules could suppress insulin release in acidic media and that release at near neutral
conditions could be manipulated by varying the amount of monomer used for polymerisation.
Subcutaneous administration of insulin-loaded nanocapsules to diabetic rats demonstrated
that the bioactivity of insulin was largely retained following this method of preparing peptide-
loaded nanocapsules and that the pharmacodynamic response was dependent on the amount
of monomer used for polymerisation. The intragastric administration of insulin-loaded
nanocapsules dispersed in the biocompatible microemulsion resulted in a signi cantly greater
reduction in blood glucose levels of diabetic rats than an aqueous insulin solution or insulin
formulated in the same microemulsion. This study demonstrates that the formulation of
peptides within PBCA nanocapsules that are administered dispersed in a microemulsion can
facilitate the oral absorption of encapsulated peptide. Such a system can be prepared in-situ by
the interfacial polymerisation of a water-in-oil biocompatible microemulsion.
Introduction
The oral route has received much attention for the delivery of macromolecules,
such as proteins and peptides, owing to its convenience and acceptability. However,
major barriers exist for the oral delivery of these bioactives. Proteolytic enzymes
present in the stomach and small intestine result in their digestion and the
absorptive epithelium eŒectively excludes absorption of such hydrophilic macro-
molecules (Zhou & Li Wan Po 1991). Various approaches have been used in an
attempt to overcome these barriers and increase the oral bioavailability of proteins
and peptides including the use of polymeric nanoparticles and microemulsions
(Damge! et al 1988, 1997; Constantinides et al 1994; Trenktrog et al 1995; Vranckx
et al 1996). Encapsulation of the protein or peptide within nanoparticles can
physically protect the bioactive from proteolytic enzymes (Lowe & Temple 1994;
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Damge! et al 1997). Further, nanoparticles have been
shown to translocate across the intestinal mucosa and
hence can facilitate the absorption of peptides from the
gut lumen (Aprahamian et al 1987; Jani et al 1990;
Florence et al 1995). Under such circumstances, the
polymer used for the preparation of the particulate
carrier must be biodegradable. Lipid-based micro-
emulsions have also proven bene® cial for improving
the oral delivery of proteins and peptides (Ritschel
1991; Constantinides et al 1994; Trenktrog et al 1995).
The mechanism by which microemulsions enhance the
oral absorption of peptides may not only be a result of
their eŒect on membrane structure and ¯ uidity (Ritschel
1991; Constantinides et al 1994; Trenktrog et al 1995)
but may also result from their ability to enhance lymph
uptake thereby overcoming hepatic ® rst-pass meta-
bolism (Ritschel 1991; Porter et al 1996).
We recently reported a method by which biodeg-
radable, aqueous cored nanocapsules suitable for the
entrapment of proteins and peptides can be prepared by
interfacial polymerisation of water-in-oil microemul-
sions using alkylcyanoacrylates (Watnasirichaikul et al
2000). The use of microemulsions as a template for
polymerisation has advantages over the use of size-
reduced kinetically stabilised water-in-oil dispersions
which have also been used for the preparation of
aqueous cored nanocapsules (Vranckx et al 1996). As
microemulsions are thermodynamically stable, they
form spontaneously upon combining the oil, surfactant
and aqueous mixture. As such, they require only a
minimal input of energy for their formation in contrast
to size-reduced kinetically stabilised water-in-oil dis-
persions. Further, microemulsions have a small and
uniform droplet size and form reproducibly yielding
nanocapsules having similar characteristics (Watnasiri-
chaikul et al 2000). If biocompatible oils and surfactants
are used for the formation of the microemulsion, the
necessity of isolating the nanocapsules from the reaction
matrix following polymerisation is removed. Poly(alkyl
cyanoacrylate) (PACA) nanocapsules can therefore be
prepared in-situ in an oily microemulsion matrix which
may prove bene® cial for the delivery of encapsulated
peptide exploiting the bene® ts of both nanocapsules
(translocation and protection) and microemulsions
(permeation enhancing eŒects and lymph delivery).
The aims of this study were to investigate whether the
biological activity of a polypeptide (insulin) is retained
following the interfacial polymerization of microemul-
sions with alkyl cyanoacrylates and to what extent the
release of peptide could be controlled by varying the
monomer mass used for polymerization. Further, the
study investigated whether PACA nanocapsules dis-
persed in a biocompatible microemulsion could facili-
tate the oral delivery of insulin in rats.
Materials and Methods
Materials
Caprylic and capric triglycerides (Crodamol GTCC),
polysorbate 80 (Crillet 4) and sorbitan mono-oleate
(Crill 4) were supplied by Croda Surfactants NZ (Auck-
land, NZ). Caprylic and capric mono- and diglycerides
(Capmul MCM)were a gift from Abitec Corp. (Colum-
bus, OH). Iso-butyl cyanoacrylate was a gift from Loc-
tite (Dublin, Ireland). Human insulin (Humulin R) was
obtained from Eli Lilly (Auckland, NZ). Streptozotocin
was purchased from Sigma (St Louis, MO). Acetonitrile
(HPLCgrade)andmethanol (ARgrade)werepurchased
from BDH (Poole, Dorset, UK). Distilled water was
used throughout. A proprietary glucose test kit (Ad-
vantage) was purchased from Roche Diagonostics
(Auckland, NZ). Male Wistar rats (180± 220 g) were
used for the pharmacodynamic study which was ap-
proved by the University of Otago Animal Ethics Com-
mittee in compliance with the Institutional Code of
Ethical Conduct, as required by The Animals Protection
Regulations 1987 which regulate the use of animals in
research, testing and teaching in New Zealand.
Preparation of nanocapsules
Microemulsions were prepared at 4 ° C by mixing 1.4 g
of the surfactant blend (polysorbate 80 and sorbitan
mono-oleate, 3 :2 weight ratio), 7.6 g of the oil mixture
(medium-chain triglycerides and medium-chain mono-
and diglycerides, 3 :1 weight ratio) and 1.0 g of a pro-
prietary human insulin aqueous solution having a con-
centration of 100 units mL­ 1 (Humulin R). Liquid iso-
butyl cyanoacrylate monomer (100, 150 or 200 mg) was
slowly added to 10 g of the microemulsion under mech-
anical stirring. The system was stirred for at least 12 h at
4 ° C for polymerisation.
Characterisation of nanocapsules
The size of the nanocapsules was determined by laser
diŒraction (Mastersizer-X, ® tted with a small-volume
dispersion unit and a 45-mm lens ; Malvern Instruments
Ltd, UK). For particle size analysis, the nanocapsule
dispersion was diluted with the microemulsion to obtain
the desired obscuration. Measurements were carried out
at room temperature.
The internal structure of the nanocapsules was visu-
alized by freeze-fracture transmission electron micro-
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scopy (Philips 410LS) as previously described (Watna-
sirichaikul et al 2000). Brie¯ y, nanocapsules were col-
lected by centrifugation at 51500 g for 60 min at 25 ° C
(Beckman J2}MC Centrifuge, JA20.1 rotor) and sand-
wiched between two copper grids. The grids were snap-
frozen by immersion in liquid propane ( ® 180° C) and
freeze-fractured using a Balzers BAF 300. Fractured
samples were shadowed with platinum (45 ° ) and carbon
(90° ). The replicas were then washed in 50% chloroform
in methanol followed by distilled water. Dried replicas
were viewed at an accelerating voltage of 80 kV.
Determination of encapsulated insulin
The polymerized insulin microemulsion (1.6 g) was di-
luted to 10 mLwithwater adjusted to pH 2.5 by addition
of hydrochloric acid. A sample of the dispersion
(300 l L)was thoroughly mixed with 300 l L of 80% v}v
methanol in water (pH 2.5). Nanocapsules and oil were
separated from the methanolic aqueous phase by centri-
fugation (12000 g for 12 min at room temperature ). The
concentration of insulin in the aqueous supernatant,
representing the insulin not associated with the nano-
capsules, was determined by HPLC as previously de-
scribed (Watnasirichaikul et al 2000). The amount of
insulin encapsulated was estimated from the diŒerence
in concentration of insulin detected in the supernatant
of a polymerized microemulsion following processing
and the concentration of insulin in the supernatant of an
unpolymerized microemulsion following the same pro-
cessing to which an equivalent concentration of insulin
had been added.
Release of insulin from nanocapsules
The release of insulin from nanocapsules was carried
out by diluting 3.2 g of the polymerized microemulsion
containing insulin to 20 mL with phosphate buŒer pH
6.8. The diluted systems were rotated longitudinally at
50 rev min­ 1 in a water-bath (37 ° C). Samples of 200 l L
were removed at various times and diluted with 200 l L
of 80% v}v methanol in water and centrifuged to
separate the aqueous fraction from the poorly water-
soluble components. The aqueous supernatant was ana-
lysed for insulin using HPLC as described for deter-
mination of encapsulated insulin. Zero-order release
rates for insulin were estimated from the linear portion
of the release rate versus time pro® le.
Release was also studied as described above under
conditions simulating those of the gastrointestinal tract.
The polymerized microemulsions containing insulin
(3.2 g)were diluted to 20 mL with water adjusted to pH
1.2 with hydrochloric acid. Release was monitored for
2 h at this pH. The pH was then adjusted to 6.8 using a
solution of Na3PO4 (0.5 m ) and the release monitored
for a further 8 h. The pH of the dissolution medium was
monitored throughout the study. Samples of 200 l L
were removed at various times and released insulin was
again analysed by HPLC as described.
Pharmacodynamic study in diabetic rats
Induction of diabetes
Diabetes was induced in maleWistar rats, 180± 220 g, by
intravenous injection of streptozotocin (70 mg kg­ 1) in
citrate buŒer pH 4.5 via the tail vein. The solution of
streptozotocin was aseptically prepared and ® ltered
through a 0.22-l m membrane ® lter (Millex-GV, Milli-
pore). Rats were considered diabetic when fasted plasma
glucose levels were greater than 300 mg dL­ 1 (typically 7
days after streptozotocin injection).
Subcutaneous administration
Diabetic rats, fasted overnight for 10 h, were injected
subcutaneously with a single dose of insulin
(10 units kg­ 1) administered in one of ® ve diŒerent for-
mulations : an aqueous solution of insulin (IN), insulin-
free nanocapsules (prepared using 150 mg monomer)
dispersed in the microemulsion (NC), the micro-
emulsions containing insulin (INME), nanocapsules
(prepared using 150 mg monomer) containing insulin
dispersed in the microemulsions (INNC 150 mg) and
nanocapsules (prepared using 200 mg monomer) con-
taining insulin dispersed in the microemulsions (INNC
200 mg). Five rats were used for each treatment group.
Intragastric administration
Four diŒerent formulations as described above (IN,
NC, INME and INNC 150 mg) were administered
intragastrically in a single dose to diabetic rats that had
been fasted overnight for 10 h. Five rats were used for
each treatment group. The dose of insulin used for
intragastric administration was 50 units kg­ 1.
Blood glucose determination
Baseline glucose levels were obtained following a 12-h
fasting period, 24 h before administration of insulin in
either study. Blood samples were taken from the tip of
the tail vein using an automatic lancing device (Softclix
II ® nger pricker, Roche). For both subcutaneous and
intragastric administration, blood samples were taken
2, 4, 6, 8, 10, 12, 16, 36 and 60 h following administra-
tion. Blood samples were analysed for blood glucose
using a proprietary glucose test kit (Advantage, Roche).
All rats had free access to water throughout the study
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and access to food during the periods 16± 24 h and
36± 48 h post administration of insulin. As such, all
blood samples were taken after at least 12 h of fasting.
Statistical analysis
Data were analysed by a one-way analysis of variance
followed by Tukey’s pairwise comparisons at a 95%
con® dence interval to test for signi® cant diŒerences




The mean of the number size distribution of three
diŒerent poly(iso-butyl cyanoacrylate) (PBCA) nano-
capsules formulations prepared using diŒerent masses
ofmonomer ranged from 200 to 210 nmwith the average
size slightly increasing with increasing mass of monomer
used for polymerisation (Table 1). Transmission elec-
Table 1 EŒect of monomer mass on size of PBCA nanocapsules,
insulin entrapment and zero-order rate constants of insulin release.




Rate constant (% min­ 1)
100 200 84.3 0.089 (60± 360)
150 210 94.7 0.055 (60± 360)
200 210 97.2 0.048 (120± 360)
Values represent means, n ¯ 2. Values in parentheses represent the
time (min) over which zero-order release was observed.
Figure1 Freeze-fracturetransmission electronmicrographofPBCA
nanocapsules.
tron micrographs of freeze-fractured samples showed
the particles to have a central cavity surrounded by a
polymer wall (Figure 1). The average size of nano-
capsules determined from the micrographs was approxi-
mately 200 nm (n " 100) in agreement with the results
from dynamic laser light scattering.
Nanoencapsulation of insulin
The entrapment of insulin within nanocapsules was in
all cases greater than 80% and increased with increasing
the mass of monomer used for polymerisation. En-
trapment e ciencies reached values of greater than 90%
for nanocapsules prepared using 150 and 200 mg of iso-
butyl cyanoacrylate when added to 10 g of micro-
emulsions containing 10% aqueous solution of insulin
(Table 1). A similar relationship between entrapment
e ciency andmass of monomer used for polymerisation
was reported by El-Samaligy et al (1986) for the en-
trapment of ¯ uorescein within nanocapsules prepared
by interfacial polymerization of kinetically stabilized
water-in-oil emulsions. The higher entrapment of this
hydrophilic marker noted with increasing monomer
mass was believed to be a result of the increased re-
sistance of thicker coats to the washing process.
Release of insulin from nanocapsules
Repeated measures analysis of variance of the release
data demonstrated that the percentage of insulin re-
leased was signi® cantly in¯ uenced by the mass of mono-
Figure 2 Release of insulin in pH 6.8 medium from PBCA nano-
capsules prepared using 100 mg (D), 150 mg (*) or 200 mg (^) of
iso-butyl cyanoacrylate added to 10 g of microemulsion. Values
represent means, n ¯ 2.
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Figure 3 Release of insulin from PBCA nanocapsules prepared
using 100 mg (E) and 150 mg (+) of iso-butyl cyanoacrylateadded to
10 g of microemulsion under conditions simulating the pH in the
gastrointestinal tract (pH was changed from 1.2 to 6.8 at 120 min).
Values represent means, n ¯ 2.
mer used for polymerisation (P ! 0.01; Figure 2). In all
cases, an initial rapid rate of insulin releasewas observed
followed by a period of slower release which appeared
zero order when release rate was plotted against time.
The zero-order release rates noted (Table 1) support the
postulated capsule nature of the nanocapsules produced
by this technique as previously evidenced by freeze-
fracture transmission electron microscopy. The decrease
in the release rate of insulin with increasing monomer
mass may be due to formation of nanocapsules having a
thicker polymer wall.
The pH of the release media was also shown to
in¯ uence the rate of insulin release from PBCA nano-
capsules. Release of insulin from PBCA nanocapsules
was suppressed in an acidic release medium (pH 1.2)
simulating the pH of the stomach over a 2-h period
(Figure 3). Changing the pH of the release medium to
6.8 after this time resulted in an immediate biphasic
release pro® le as observed when release was monitored
in only a pH 6.8 release medium. Only slight diŒerences
in the release pro® les at pH 6.8 were observed between
nanocapsules exposed for 2 h to an acidic release me-
dium and those which had not been exposed to acid
(Figure 4). These slight diŒerences were only observed
during the initial burst release (® rst 30 min)where release
from PBCA nanocapsules which had been exposed to
the acidicmediumwas slightly higher. The lackof release
under acidic conditions and hence potential protection
of insulin from the hostile environment of the stomach
Figure 4 Release of insulin from PBCA nanocapsules prepared
using 100 mg (circles) and 150 mg (squares)of iso-butyl cyanoacrylate
in pH 6.8 medium with (® lled symbols) or without (open symbols) a
2-h exposure to pH 1.2 release medium.
is in agreement with the results of Scherer et al (1994)
and could be a result of either the stability of the PBCA
under acidic conditions or due to the formation of
poly(cyano acrylic acid) following hydrolysis of the
butyl side-chain which could behave as an enteric-
coating polymer. The similarities between release pro-
® les for nanocapsules exposed for 2 h to an acidic release
medium and those which had not been exposed to acid
would suggest that suppression of release is a result of
the stability of the PBCA. However, the possibility of
some hydrolysis occurring over the 2-h period cannot
be discounted and may explain the slight diŒerences
noted in the burst release pro® les (Figure 4).
Subcutaneous administration
The process used for the preparation of nanocapsules
could potentially denature the protein or peptide being
entrapped or alternatively the protein or peptide could
become involved in the polymerisation. Either of these
processes could render the protein or peptide inactive.
The activity of insulin nanocapsules was thus ® rst evalu-
ated following subcutaneous administration. Further,
two batches of nanocapsules were prepared using dif-
ferent masses of monomer (150 and 200 mg) to in-
vestigate whether the diŒerence in release pro® les ob-
served in-vitro from nanocapsules prepared using dif-
ferent masses of monomer translated to diŒerent release
pro® les in-vivo.
All formulations containing insulin (IN, INME,
INNC 150 mg or INNC 200 mg) eŒectively reduced
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Figure 5 Blood glucose response in diabetic rats following the
subcutaneous administration of insulin-free nanocapsules (prepared
using 150 mg monomer) dispersed in the microemulsion (NC;+), an
aqueoussolution of insulin (IN;V), microemulsion containing insulin
(INME; _), nanocapsules (prepared using 150 mg monomer) con-
taining insulin dispersed in the microemulsions (INNC 150 mg;D) or
nanocapsules (prepared using 200 mg monomer) containing insulin
dispersed in the microemulsions (INNC 200 mg ;*). Values represent
means³ s.e.m., n ¯ 5.
blood glucose in diabetic rats following subcutaneous
administration (Figure 5). The pharmacodynamic eŒect
was delayedwhen insulin was administered in themicro-
emulsion compared with insulin administration as an
aqueous solution (P ! 0.05 at 2 h). The eŒect was
further delayed when insulin was encapsulated within
nanocapsules and administered dispersed in the micro-
emulsion. The extent of this delay was dependent on the
mass of monomer used for polymerisation. Nanocap-
sules prepared using 200 mg of monomer added to
10 mL of a microemulsion containing 10% insulin
solution not only reduced the extent of the initial drop in
blood sugar but signi® cantly prolonged the pharmaco-
dynamic eŒect compared with nanocapsules prepared
using 150 mg monomer (P ! 0.05 at 36 h). The subcu-
taneous study therefore showed that the bioactivity of
insulin is largely retained following the interfacial
polymerisation of a microemulsion using alkyl cyano-
acrylates and that the release of insulin can indeed
be controlled by varying the amount of monomer used
for polymerisation, hence varying the polymer wall
thickness of the nanocapsules.
Intragastric administration
The resulting blood glucose (as percentage of baseline
value) following the intragastric administration of
empty nanocapsules dispersed in microemulsion (NC),
an aqueous insulin solution (IN), insulin formulated in
a microemulsion (INME) and insulin encapsulated
Figure 6 Blood glucose response in diabetic rats following the
intragastric administration of insulin-free nanocapsules (prepared
using 150 mg monomer) dispersed in the microemulsion (NC;+), an
aqueoussolution of insulin (IN;V), microemulsion containing insulin
(INME; _) or nanocapsules (prepared using 150 mg monomer)
containing insulin dispersed in the microemulsions (INNC 150 mg;
D). Values represent means³ s.e.m., n ¯ 5.
within nanocapsules prepared using 150 mg monomer
(INNC 150 mg) and administered dispersed in the
microemulsion are shown in Figure 6. For empty nano-
capsules, blood glucose was noted to decrease with time,
as was noted for the same formulation in the subcu-
taneous study, and was attributed to the continued
fasting status of the diabetic rats. No signi® cant diŒer-
ence in blood glucose reduction (% of initial value) was
observed between administration of an aqueous insulin
solution and empty nanocapsules at any of themeasured
time points (P " 0.05). A signi® cant diŒerence in blood
glucose reduction between empty nanocapsules and the
insulin microemulsion was observed only at 10 h post-
administration (P ! 0.05). A signi® cant diŒerence in
blood glucose levels was observed between 4 and 16 h
for INNC 150 mg and empty nanocapsules and between
6 and 16 h for INNC 150 mg and either the aqueous
insulin solution or the insulin microemulsion. Thus, a
formulation in which insulin is encapsulated within
nanoparticles and administered dispersed in a micro-
emulsion is more eŒective in improving the oral bio-
availability of insulin than a microemulsion alone.
Whether this is a result of enhanced protection against
proteolytic enzymes or the ability of nanocapsules to
translocate across the intestinal mucosa and hence
facilitate intestinal absorption remains to be deter-
mined, as is the importance of administering the nano-
capsules dispersed in a microemulsion.
The release studies carried out in-vitro demonstrated
that PBCA nanocapsules could suppress the release of
insulin under acidic conditions (pH 1.2) and hence may
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protect the entrapped protein during its passage through
the stomach where it has been reported that up to 30%
of protein digestion can occur (Verhoef et al 1990).
When exposed to media having a pH similar to that
expected in the intestine (pH 6.8), a signi® cant pro-
portion of the insulin is immediately released (approx
40% burst release). As mentioned, microemulsions in-
corporating medium-chain glycerides have been report-
ed to enhance peptide absorption (Ritschel 1991; Con-
stantinides et al 1994). The release of insulin in the
intestine in the presence of the microemulsion excipients
could therefore facilitate the intestinal absorption of
some of this released insulin before enzymatic digestion
and lead to the early absorption of insulin as noted in
this investigation, with eŒects being noted as early as 2 h
post intragastric administration.
The prolonged duration of the eŒect on blood glucose
noted in this study lasting up to 60 h post intragastric
administration, however, would suggest that the sus-
tained release of insulin entrapped in nanocapsules plays
a role in the overall response and that the gastro-
intestinal transit of the nanoparticles is either delayed or
the particles must passage across the intestinal mucosa.
A prolonged reduction in blood glucose in diabetic rats
of 10± 13 days was reported by Damge! et al (1997)
following the intragastric administration of insulin-
loaded nanospheres dispersed in an oily medium (Migl-
yol 812) containing surface active agents. Using radio-
labelled polymer and insulin, these workers investigated
the tissue distribution of nanospheres and insulin fol-
lowing intragastric administration and concluded that
the prolonged eŒect was due, in part, to the progressive
arrival of nanospheres from the stomach to the intestine
and a prolonged mucoadhesion of nanospheres, leading
to a delayed absorption and also to the absorption of
intact nanospheres or at least small oligomers linking
insulin. The diŒerence in persistence of the pharma-
codynamic eŒect of greater than a week observed be-
tween this study and that of Damge! et al (1997) is
di cult to interpret but could be a result of the diŒerence
in release characteristics between the nanocapsules used
in this investigation and the nanospheres used byDamge!
et al, diŒerence in the vehicle used to disperse and
administer the nanoparticles, diŒerence in the amount
of insulin oligomers formed in the two methods of
nanoparticle preparation or diŒerence in dose of insulin
administered (50 units kg­ 1 cf 100 units kg­ 1).
The ® ndings of this study further lend support to the
importance of the vehicle used to disperse and admin-
ister the nanoparticles. Both Lowe& Temple (1994) and
Damge! et al (1997) have reported that nanocapsules
dispersed in water are ineŒective in enhancing the oral
absorption of entrapped peptide. Damge! et al (1997)
proposed that the dispersion of the nanocapsules in an
oily vehicle containing surfactants was a prerequisite for
oral-absorption-enhancing eŒects for encapsulated pep-
tides. However, using the more commonly usedmethods
for the preparation of PACA nanocapsules, the peptide-
loaded nanoparticles must ® rst be isolated from the
polymerisation vehicle before they can be dispersed in
such a vehicle. By using a biocompatible water-in-oil
microemulsion as a template for polymerisation as
described in this study, peptide-loaded nanocapsules are
formed in-situ in a vehicle reportedly capable of pro-
moting intestinal absorption. This overcomes the need
for isolation and renders the process very amenable to
scale-up.
Conclusion
Varying the mass of monomer used for polymerisation
can control the rate of release of insulin from PBCA
nanocapsules prepared by the interfacial polymerisation
of a water-in-oil microemulsion as demonstrated both
in-vitro and in-vivo following subcutaneous admini-
stration. The releaseof insulin from PBCAnanocapsules
is suppressed in acidic conditions and release in near
neutral conditions is not dramatically altered by pre-
exposure to an acidic environment. This would suggest
that PBCA would remain largely intact during transit
through the stomach. The formulation of insulin within
nanocapsules dispersed in the water-in-oil microemu-
lsion has been shown in this study to signi® cantly
increase the oral bioavailability of insulin in diabetic
rats following intragastric administration compared
with an aqueous insulin solution or a water-in-oil insulin
microemulsion. Whether this is a result of enhanced
protection against proteolytic enzymes aŒorded by en-
capsulation, the ability of nanocapsules to translocate
across the intestinal mucosa and hence facilitate
intestinal absorption or some synergistic eŒect of the
microemulsion vehicle remains to be determined and
is the subject of continuing investigations.
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